Professor Ben van Hout
Professor of Health Economics
University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 0827
Fax: (+44) (0)114 222 0749
I joined ScHARR in November 2009 as Professor of Health Economics.
I have extensive experience in modelling and have contributed to the methodology of economic evaluation in various areas. In 1993 I was one of the earliest researchers to apply discrete event models and was the first to apply a non-parametric method to estimate costs in the presence of censoring. In 1994 I was the first to apply Fieller´s approach to calculate confidence intervals around cost-effectiveness ratios, and I introduced the acceptability curve, which is now a well known concept in cost effectiveness analysis. In 1996 I was one of the first to apply probabilistic sensitivity analysis. In 2000 I was one of the initial people to explore Bayesian techniques in economic evaluation. I have had work published on discounting and estimating utility functions.
I am one of the founding members of the EuroQol group and I currently enjoy chairing the valuation task force within the EQ-5D group. My experience covers several therapeutic areas, including renal disease, cancer, osteoporosis, sepsis, schizophrenia, blood safety and most notably cardiovascular disease. My main interest concerns the use of elegant techniques, mostly to solve practical problems, but sometimes also because of the elegance itself.
Ben van Hout is based half-time in Health Economics and Decision Science (HEDS).
- Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R & van Hout B (2016) Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39(6), 313-320. View this article in WRRO
- Devlin NJ, Shah KK, Mulhern B & van Hout B (2015) A new valuation method: direct elicitation of personal utility functions for EQ-5D. QUALITY OF LIFE RESEARCH, 24, 176-176.
- Begum N, Stephens S, Schoeman O, Fraschke A, Kirsch B, Briere J-B, Verheugt FWA & van Hout BA (2015) Cost-effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Sweden. Cardiology and Therapy, 4(2), 131-153. View this article in WRRO
- Stephens S, Botteman MF, Cifaldi MA & van Hout BA (2015) Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease. BMJ Open, 5(6). View this article in WRRO
- Thomas JA, Tubaro A, Barber N, Thorpe A, Armstrong N, Bachmann A & Van Hout B (2015) The Continuing Story of the Cost-Effectiveness of Photoselective Vaporization of the Prostate versus Transuretheral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Obstruction. Value in Health, 18(4), 376-386.
- Rowen D, Brazier J & Van Hout B (2015) A Comparison of Methods for Converting DCE Values onto the Full Health-Dead QALY Scale. Medical Decision Making, 35(3), 328-340. View this article in WRRO
- Golicki D, Niewada M, Hout BV, Janssen MF & Pickard AS (2014) Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe. Value in Health Regional Issues, 4, 19-23.
- Krabbe PFM, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS & Xie F (2014) Multinational Evidence of the Applicability and Robustness of Discrete Choice Modeling for Deriving EQ-5D-5L Health-State Values. Medical Care, 52(11), 935-943. View this article in WRRO
- Ara R, Kearns B, vanHout BA & Brazier JE (2014) Predicting preference-based utility values using partial proportional odds models.. BMC Res Notes, 7, 438. View this article in WRRO
- Heeg BM & van Hout BA (2014) Assessing uncertainties surrounding combined endpoints for use in economic models.. Med Decis Making, 34(3), 300-310.
- Mulhern B, Devlin N, Shah K, Feng Y & Van Hout B (2013) Developing an EQ-5D-5L value set for England. QUALITY OF LIFE RESEARCH, 22.